By Benjamin Chiou
Date: Thursday 17 Apr 2025
(Sharecast News) - Shares in Eli Lilly & Co were set to soar on Wednesday on the back of positive results of a late-stage trial of its weight-loss pill Orforglipron, which is thought to be a needle-free alternative to Novo Nordisk's popular injectable Ozempic drug.
Lilly said a Phase 3 trial...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news